Aligos Therapeutics Inc
ALGS
Market Cap$47.94M
Close$
$0.17
97.9% downside
Current Fair Value
97.9% downsideOvervalued by 97.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $47.94 Million |
|---|---|
| Enterprise Value | $-17,948,968.00 |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-20.94 |
| Beta | 2.69 |
| Outstanding Shares | 8,408,481 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.24 |
|---|---|
| PEG | 0.55 |
| Price to Sales | - |
| Price to Book Ratio | 0.63 |
| Enterprise Value to Revenue | -8.97 |
| Enterprise Value to EBIT | 0.21 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.44 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Aligos Therapeutics Inc
80 employeesAligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and de...